Search Results

You are looking at 151 - 160 of 1,415 items for :

  • "carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Integration of Systemic and Liver-Directed Therapies for Locally Advanced Hepatocellular Cancer: Harnessing Potential Synergy for New Therapeutic Horizons

Eric H. Bent, Eric Wehrenberg-Klee, Eugene J. Koay, Lipika Goyal, and Jennifer Y. Wo

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death and the sixth most common cancer type worldwide. 1 In 2020, there were an estimated 42,810 new patients with liver cancers and 30,160 deaths from liver cancers in the

Full access

The Role of MRI in Breast Cancer Screening

Constance D. Lehman and Robert A. Smith

associated with ductal carcinoma in situ (DCIS) rather than invasive lesions. In a study of 1909 women at increased risk for breast cancer, Kriege et al. 17 found that 5 of 8 cancers detected with mammography but missed on MRI were DCIS lesions. However

Full access

Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical Outcomes

Rahul Aggarwal, Tian Zhang, Eric J. Small, and Andrew J. Armstrong

and outcomes of NEPC Outline treatment options for patients with NEPC Neuroendocrine prostate cancer (NEPC) is a lethal form of prostate cancer, with most patients dying within 1 to 2 years of diagnosis. 1 , 2 Pure localized small cell carcinoma

Full access

Predictive Biomarkers for Molecularly Targeted Therapies in Renal Cell Carcinoma

James Brugarolas

A significant challenge in oncology is the identification of predictive biomarkers of therapeutic benefit. The article in this issue by Fay et al (page 820 ) illustrates this issue in renal cell carcinoma (RCC). The challenge encompasses all RCC

Full access

Contemporary Intravesical Treatment Options for Urothelial Carcinoma of the Bladder

Stephen A. Brassell and Ashish M. Kamat

. Lamm DL Herr H Jakse G . Updated concepts and treatment of carcinoma in situ . Urol Oncol 1998 ; 4 : 130 – 135 . 4. Abel PD . Follow-up of patients with ``superficial'' transitional cell carcinoma of the bladder: the case for a change in

Full access

Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors

Jay Gong, Jeffrey P. Gregg, Weijie Ma, Ken Yoneda, Elizabeth H. Moore, Megan E. Daly, Yanhong Zhang, Melissa J. Williams, and Tianhong Li

variants other than EML4-ALK V1, V3, or different fusion partners affect the clinical benefit of ALK inhibitors. Histologic transformation from lung adenocarcinoma (LUAD) to small cell lung carcinoma (SCLC) or large cell neuroendocrine tumor has been

Full access

Complications of Radioactive Iodine Treatment of Thyroid Carcinoma

Stephanie L. Lee

the small risk for second primary malignancy in patients with stage II thyroid carcinoma, but patients should be counseled that the risks for this occurrence, especially leukemia, are low but are still a real risk associated with RAI therapy

Full access

Molecular Targets and Therapies for Ampullary Cancer

Monica Arun Patel, Jeremy D. Kratz, Alexander S. Carlson, Ysaith Orellana Ascencio, Broc S. Kelley, and Noelle K. LoConte

intestinal and pancreatobiliary subtypes, which confer selected alterations that can guide treatment. Anatomy and Pathology of Ampullary Cancer Periampullary carcinoma describes neoplasms arising from the head of the pancreas, distal common bile duct (CBD

Full access

Predictors of Nonadherence to NCCN Guideline Recommendations for the Management of Stage I Anal Canal Cancer

Adam J. Kole, John M. Stahl, Henry S. Park, Sajid A. Khan, and Kimberly L. Johung

recommended definitive CRT for all patients with locoregional anal canal cancer since the inception of the second version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Anal Carcinoma in 2002. 2 , 17 Whether NCCN Guidelines are

Full access

Basal Cell and Squamous Cell Skin Cancers

Stanley J. Miller, Murad Alam, James Andersen, Daniel Berg, Christopher K. Bichakjian, Glen Bowen, Richard T. Cheney, L. Frank Glass, Roy C. Grekin, Anne Kessinger, Nancy Y. Lee, Nanette Liegeois, Daniel D. Lydiatt, Jeff Michalski, William H. Morrison, Kishwer S. Nehal, Kelly C. Nelson, Paul Nghiem, Thomas Olencki, Clifford S. Perlis, E. William Rosenberg, Ashok R. Shaha, Marshall M. Urist, Linda C. Wang, and John A. Zic

their incidence is rising rapidly. 3 , 4 Basal cell carcinomas are approximately 4 to 5 times more common than squamous cell carcinomas. Although rarely metastatic, basal and squamous cell cancers can produce substantial local destruction along with